Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome
JAMA Neurology · 01.05.2023 · 80 (5) · 495
DOI: 10.1001/jamaneurol.2023.0488 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Neurology, erschienen am 01.05.2023. Verfasst von Lawren VandeVrede und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Memory and Aging Center, University of California San Francisco Weill Institute for Neurosciences, University of California,…. Hauptthemen laut MEDLINE: Alzheimer Disease, Corticobasal Degeneration, Supranuclear Palsy, Progressive, Frontotemporal Lobar Degeneration. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIMH NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Importance Plasma phosphorylated tau217 (p-tau217), a biomarker of Alzheimer disease (AD), is of special interest in corticobasal syndrome (CBS) because autopsy studies have revealed AD is the driving neuropathology in up to 40% of cases. This differentiates CBS from other 4-repeat tauopathy (4RT)–associated syndromes, such as progressive supranuclear palsy Richardson syndrome (PSP-RS) and nonfluent primary progressive aphasia (nfvPPA), where underlying frontotemporal lobar degeneration (FTLD) is typically the primary neuropathology.
Objective
To validate plasma p-tau217 against positron emission tomography (PET) in 4RT-associated syndromes, especially CBS. Design, Setting, and Participants This multicohort study with 6, 12, and 24-month follow-up recruited adult participants between January 2011 and September 2020 from 8 tertiary care centers in the 4RT Neuroimaging Initiative (4RTNI). All participants with CBS (n = 113), PSP-RS (n = 121), and nfvPPA (n = 39) were included; other diagnoses were excluded due to rarity (n = 29). Individuals with PET-confirmed AD (n = 54) and PET-negative cognitively normal control individuals (n = 59) were evaluated at University of California San Francisco. Operators were blinded to the cohort. Main Outcome and Measures Plasma p-tau217, measured by Meso Scale Discovery electrochemiluminescence, was validated against amyloid-β (Aβ) and flortaucipir (FTP) PET. Imaging analyses used voxel-based morphometry and bayesian linear mixed-effects modeling. Clinical biomarker associations were evaluated using longitudinal mixed-effect modeling.
Results
Of 386 participants, 199 (52%) were female, and the mean (SD) age was 68 (8) years. Plasma p-tau217 was elevated in patients with CBS with positive Aβ PET results (mean [SD], 0.57 [0.43] pg/mL) or FTP PET (mean [SD], 0.75 [0.30] pg/mL) to concentrations comparable to control individuals with AD (mean [SD], 0.72 [0.37]), whereas PSP-RS and nfvPPA showed no increase relative to control. Within CBS, p-tau217 had excellent diagnostic performance with area under the receiver operating characteristic curve (AUC) for Aβ PET of 0.87 (95% CI, 0.76-0.98; P < .001) and FTP PET of 0.93 (95% CI, 0.83-1.00; P < .001). At baseline, individuals with CBS-AD (n = 12), defined by a PET-validated plasma p-tau217 cutoff 0.25 pg/mL or greater, had increased temporoparietal atrophy at baseline compared to individuals with CBS-FTLD (n = 39), whereas longitudinally, individuals with CBS-FTLD had faster brainstem atrophy rates. Individuals with CBS-FTLD also progressed more rapidly on a modified version of the PSP Rating Scale than those with CBS-AD (mean [SD], 3.5 [0.5] vs 0.8 [0.8] points/year; P = .005). Conclusions and Relevance In this cohort study, plasma p-tau217 had excellent diagnostic performance for identifying Aβ or FTP PET positivity within CBS with likely underlying AD pathology. Plasma P-tau217 may be a useful and inexpensive biomarker to select patients for CBS clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Memory and Aging Center, University of California San Francisco Weill Institute for Neurosciences, University of California, San Francisco.
- Lawrence Berkeley National Laboratory, Berkeley, California.
- Neurochemistry Laboratory, Department of Clinical Chemistry, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
- Fixel Institute for Neurological Disease, Department of Clinical and Healthy Psychology, University of Florida, Gainesville.
- Associate Editor, JAMA Neurology.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota.
Förderung
- NIA NIH HHS
- NIMH NIH HHS
Zitieren
APA
VandeVrede, L., La Joie, R., Thijssen, E. H., Asken, B. M., Vento, S. A., Tsuei, T., Baker, S. L., Cobigo, Y., Fonseca, C., Heuer, H. W., Kramer, J. H., Ljubenkov, P. A., Rabinovici, G. D., Rojas, J. C., Rosen, H. J., Staffaroni, A. M., Boeve, B. F., Dickerson, B. C., Grossman, M., …, & Boxer, A. L. (2023). Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome. JAMA Neurology, 80(5), 495. https://doi.org/10.1001/jamaneurol.2023.0488
Vancouver
VandeVrede L, La Joie R, Thijssen EH, Asken BM, Vento SA, Tsuei T, et al. Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome. JAMA Neurology. 2023;80(5):495. doi:10.1001/jamaneurol.2023.0488
BibTeX
@article{VandeVrede2023,
author = {VandeVrede, Lawren and La Joie, Renaud and Thijssen, Elisabeth H and Asken, Breton M and Vento, Stephanie A and Tsuei, Torie and Baker, Suzanne L and Cobigo, Yann and Fonseca, Corrina and Heuer, Hilary W and Kramer, Joel H and Ljubenkov, Peter A and Rabinovici, Gil D and Rojas, Julio C and Rosen, Howie J and Staffaroni, Adam M and Boeve, Brad F and Dickerson, Brad C and Grossman, Murray and Huey, Edward D and Irwin, David J and Litvan, Irene and Pantelyat, Alexander Y and Tartaglia, Maria Carmela and Dage, Jeffrey L and Boxer, Adam L},
title = {Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome},
journal = {JAMA Neurology},
year = {2023},
volume = {80},
number = {5},
pages = {495},
doi = {10.1001/jamaneurol.2023.0488}
}
EUVIMED